Skin Clearance, Treatment Response Off-Therapy, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-Week Phase 3 Trial in Adults and Children Down to 2 Years of Age With Atopic Dermatitis. J of Skin 2024, 8 (6), s460. https://doi.org/10.25251/skin.8.supp.460.